Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2018 Nov 13;18(2):346–355. doi: 10.1158/1535-7163.MCT-18-0510

Figure 1. Patients with activating alterations in phosphoinositide-3 kinase (PI3K) signaling are commonly identified and have minimal benefit from MTORC1 inhibition.

Figure 1.

Fifteen patients with cancers possessing activating alterations within the PI3K pathway were identified in the University of Wisconsin Carbone Cancer Center Precision Medicine Molecular Tumor Board Registry. These mutations were identified in diverse cancers. Of these patients 6 of them were treated with everolimus. One patient with breast cancer received this therapy in combination with a hormonal agent resulting in stable disease for 226 days. The other five patients had progressive disease with most discontinuing therapy within 60 days secondary to clinical progression. Testing method: 1 = Foundation One; 2 = Foundation ICE; 3 = University of Wisconsin Cancer Gene Mutation Panel; 4 = Foundation T5a; 5 = NCI-MATCH. NA = not applicable.